Clinical Trials Directory

Trials / Completed

CompletedNCT01362595

Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
55 (actual)
Sponsor
Northwell Health · Academic / Other
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

This study will determine the safety and possibility of giving the amino acid, leucine, in patients with Diamond Blackfan anemia(DBA)who are on dependent on red blood cell transfusions. The leucine is expected to produce a response in patients with DBA to the point where red blood cell production is increased. Red cell transfusions can then be less frequent or possibly discontinued. The investigators will study the side effects, if any, of giving leucine to DBA patients. Leucine levels of leucine will be obtained at baseline and during the study. The drug leucine will be provided in capsule form and taken 3 times a day for a total of 9 months.

Detailed description

Leucine will be provided to participants in the form of a capsule and will be taken three times daily. Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months. The entire study will last 12-15 months in length. Subjects must be two years of age or older and on transfusion for more than six months prior to enrollment.

Conditions

Interventions

TypeNameDescription
DRUGleucineDosage of leucine will be dependent on body surface area (BSA): leucine 700 mg/m2/dose by mouth three times a day

Timeline

Start date
2013-06-01
Primary completion
2018-06-30
Completion
2020-11-30
First posted
2011-05-30
Last updated
2022-12-02
Results posted
2022-12-02

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01362595. Inclusion in this directory is not an endorsement.